Evidence map›Paper›PMID 34719866›Full record

ArticleThe clinical respiratory journal2022

Nasal high flow therapy use in wards in patients with chronic obstructive pulmonary disease may spare ICU resources.

Matthew W Trump, Iaswarya Ganapathiraju, Julie A Jackson, Kate Branick, Matt Taylor, Trevor W Oetting, Carol A Pelaez

Open access · hybridAbstract read
In one paragraph

Article in The clinical respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Matthew W TrumpPulmonary and Critical Care Medicine, The Iowa Clinic, Des Moines, IA, USA.
Iaswarya GanapathirajuUniversity of Iowa - Des Moines Internal Medicine Program, UnityPoint Health, Des Moines, IA, USA.
Julie A JacksonRespiratory Therapy, UnityPoint Health, Des Moines, IA, USA.
Kate BranickUniversity of Iowa - Des Moines Internal Medicine Program, UnityPoint Health, Des Moines, IA, USA.
Matt TaylorUniversity of Iowa - Des Moines Internal Medicine Program, UnityPoint Health, Des Moines, IA, USA.
Trevor W OettingRespiratory Therapy, UnityPoint Health, Des Moines, IA, USA.
Carol A PelaezTrauma Surgery, The Iowa Clinic, Des Moines, IA, USA.
UnityPoint Health · USIowa Lutheran Hospital · USUniversity of Iowa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasal high flow therapy has been previously studied for the management of acute hypoxic respiratory failure in patients with chronic obstructive pulmonary disease but the data regarding its use outside of the intensive care unit are sparse. We aimed to evaluate safety and efficacy of nasal high flow therapy outside of the intensive care unit in patients with acute hypoxic respiratory failure and known chronic obstructive pulmonary disease. We conducted a retrospective matched historic cohort study of adult patients with diagnosed chronic obstructive pulmonary disease presenting with acute hypoxic respiratory failure between December 2017 to June 2019, after the initiation of a new protocol, which allowed patients to be managed with nasal high flow therapy on the medical/surgical wards instead of transferring them to the ICU per prior standard of care. Nasal high flow therapy was initiated either in the emergency department or on the medical/surgical wards. Patients were matched with historical cohorts who were managed with prior standard of care based on age, body mass index, comorbidities, and home oxygen use. Primary outcome of interest was difference in rates of mechanical ventilation. Secondary outcomes included hospital length of stay, total number of days spent in the intensive care unit, and in-hospital mortality. A total of 90 patients met study inclusion criteria and were matched to 90 historical control patients. Among the study group, 8% required mechanical ventilation versus 9% in the control group (p = 0.79). Hospital length of stay was 7 days in study group versus 6 days in control group (p = 0.02), and in-hospital mortality was the same in both study and control groups at 12% (p = 0.99). Nineteen percent of study group patients required ICU level of care at any time during the admission compared with 49% of control group (p < 0.001). Nasal high flow therapy use in patients with acute hypoxic respiratory failure and underlying chronic obstructive pulmonary disease outside of the intensive care unit may spare ICU resources and cost without delay in definitive care such as mechanical ventilation.

Indexed as

Pulmonary Disease, Chronic ObstructiveRespiratory InsufficiencyAdultCohort StudiesHospitalsHumansIntensive Care UnitsOxygen Inhalation TherapyRespiration, ArtificialRetrospective Studiesacute hypoxic respiratory failurechronic obstructive pulmonary diseaseICUnasal high flow

Identifiers

PMID34719866
PMCPMC9060061
OpenAlexW3210622454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.